Metastatic melanoma: ESMO 2025 updates in 2 minutes
Three key clinical questions were addressed at ESMO 2025: the role of vaccines in first-line therapy, management of PD-1-resistant disease, and optimal treatment duration. Associate Professor Marco Donia, MD, PhD, University of Copenhagen & Clinician-Scientist at Herlev Hospital, Denmark, summarizes the main findings and their implications for treatment decisions in metastatic melanoma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
